Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
October 18 2021 - 4:54PM
Dow Jones News
By Stephen Nakrosis
Biopharmaceutical company Calithera Biosciences Inc. on Monday
said was expanding its oncology pipeline as it agreed to acquire
two clinical-stage compounds from Takeda Pharmaceutical Co.
Ltd.
Calithera said the compounds, sapanisertib and mivavotinib,
strengthen its pipeline of clinical-stage targeted therapies. Susan
Molineaux, the company's president and chief executive, said "We
believe that these clinical-stage compounds are an excellent
complement to our internally-developed pipeline programs, and fit
well with our current strategic focus on biomarker-driven
therapeutic approaches."
She also said the company plans to start clinical trials for
both compounds and generate data in the next 12 to 18 months.
At 4:18 p.m. ET, Calithera stock had risen 4.48% to $2.10.
The stock finished the day's regular-trading session with a
1.47% loss, closing at $2.01 a share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 18, 2021 16:39 ET (20:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Apr 2024 to May 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From May 2023 to May 2024